Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

289.02 +0.15 (+0.05%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,262,438
Open 285.58
Bid (Size) 284.50 (2)
Ask (Size) 286.00 (4)
Prev. Close 288.87
Today's Range 284.52 - 290.48
52wk Range 253.30 - 346.85
Shares Outstanding N/A
Dividend Yield 3.11%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Amgen Surpasses Q4 Earnings Forecasts
Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth. 
Via The Motley Fool
Earnings Summary: Amgen Q4
Via Benzinga

Performance

YTD
+11.47%
+11.47%
1 Month
+11.77%
+11.77%
3 Month
-9.48%
-9.48%
6 Month
-12.14%
-12.14%
1 Year
-10.23%
-10.23%

More News

Read More
Amgen’s (NASDAQ:AMGN) Q4 Sales Top Estimates, Full-Year Outlook Slightly Exceeds Expectations
Via StockStory
Amgen Beat Fourth-Quarter Expectations. So, Why Did Shares Tumble?
Via Investor's Business Daily
These Were the 5 Top-Performing Stocks in the Dow Jones Industrial Average in January 2025
Via The Motley Fool
Topics Stocks
Exposures US Equities
Analyst Expectations For Amgen's Future
Via Benzinga
This Is What Whales Are Betting On Amgen
Via Benzinga
Unpacking the Latest Options Trading Trends in Amgen
Via Benzinga
Peering Into Amgen's Recent Short Interest
Via Benzinga
US Stocks Rise Despite China's Trade Fears, Palantir Defies Gravity, Gold Rallies Further: What's Driving Markets Tuesday?
Via Benzinga
Earnings Scheduled For February 4, 2025
Via Benzinga
Markets React To Softening Trade Tariff Policy
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
The Dogs Of The Dow 2025
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Friday's pre-market session: top gainers and losers in the S&P500 index
Via Chartmill
These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024
Via The Motley Fool
Topics Stocks
Exposures US Equities
Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial Results
Via Investor's Business Daily
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Via Benzinga
Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
Via Benzinga
Topics Economy
Exposures Interest Rates
FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation
Via Benzinga
Exposures Product Safety
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows
Via The Motley Fool
What Lies Ahead In 2025? Slower Growth, More Volatility
Via Talk Markets
Topics Economy Stocks / Equities
Exposures Economy
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.
Via The Motley Fool
3 High-Yield Dividend Stocks to Buy in 2025
Via The Motley Fool
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.